RT @MCT_AACR: Attending the Drug Resistance: Challenges and Prospects educational session at #AACR22? Check out this #FirstDisclosure paper…
Attending the Drug Resistance: Challenges and Prospects educational session at #AACR22? Check out this #FirstDisclosure paper on TPX-0131, a next-generation ALK inhibitor that targets an array of ALK resistance mutations including G1202R. https://t.co/gdCx
RT @MCT_AACR: Preclinical studies show that TPX-0131 is a CNS-penetrant, next-generation ALK inhibitor with potency against wild-type ALK a…
RT @MCT_AACR: Preclinical studies show that TPX-0131 is a CNS-penetrant, next-generation ALK inhibitor with potency against wild-type ALK a…
Preclinical studies show that TPX-0131 is a CNS-penetrant, next-generation ALK inhibitor with potency against wild-type ALK and a spectrum of acquired resistance mutations for which there are no effective therapies. https://t.co/zUxohOLnaS. #FirstDisclosur
Preclinical studies show that TPX-0131 is a CNS-penetrant, next-generation ALK inhibitor with potency against wild-type ALK and a spectrum of acquired resistance mutations for which there are no effective therapies. https://t.co/mpdo0NUntN #FirstDisclosure
Preclinical studies show that TPX-0131 is a CNS-penetrant, next-generation ALK inhibitor with potency against wild-type ALK and a spectrum of acquired resistance mutations for which there are no effective therapies. https://t.co/vhJazqy3ev https://t.co/rO9
Preclinical studies show that TPX-0131 is a CNS-penetrant, next-generation ALK inhibitor with potency against wild-type ALK and a spectrum of acquired resistance mutations for which there are no effective therapies. https://t.co/8xSPU4lwhb https://t.co/Txw
Preclinical studies show that TPX-0131 is a CNS-penetrant, next-generation ALK inhibitor with potency against wild-type ALK and a spectrum of acquired resistance mutations for which there are no effective therapies. https://t.co/OF7OqzOHUT https://t.co/qhR
Preclinical studies show that TPX-0131 is a CNS-penetrant, next-generation ALK inhibitor with potency against wild-type ALK and a spectrum of acquired resistance mutations for which there are no effective therapies. https://t.co/8iyn4akda4 https://t.co/zMD
RT @StephenVLiu: Online @MCT_AACR - preclinical account of TPX-0131, a potent, CNS-penetrant, next-generation #ALK inhibitor. This macrocyc…
RT @StephenVLiu: Online @MCT_AACR - preclinical account of TPX-0131, a potent, CNS-penetrant, next-generation #ALK inhibitor. This macrocyc…
RT @StephenVLiu: Online @MCT_AACR - preclinical account of TPX-0131, a potent, CNS-penetrant, next-generation #ALK inhibitor. This macrocyc…
RT @StephenVLiu: Online @MCT_AACR - preclinical account of TPX-0131, a potent, CNS-penetrant, next-generation #ALK inhibitor. This macrocyc…
$TPTX
RT @StephenVLiu: Online @MCT_AACR - preclinical account of TPX-0131, a potent, CNS-penetrant, next-generation #ALK inhibitor. This macrocyc…
RT @StephenVLiu: Online @MCT_AACR - preclinical account of TPX-0131, a potent, CNS-penetrant, next-generation #ALK inhibitor. This macrocyc…
Another interesting #ALK Inhibitor is coming. Looking foward for it!
RT @StephenVLiu: Online @MCT_AACR - preclinical account of TPX-0131, a potent, CNS-penetrant, next-generation #ALK inhibitor. This macrocyc…
RT @StephenVLiu: Online @MCT_AACR - preclinical account of TPX-0131, a potent, CNS-penetrant, next-generation #ALK inhibitor. This macrocyc…
RT @StephenVLiu: Online @MCT_AACR - preclinical account of TPX-0131, a potent, CNS-penetrant, next-generation #ALK inhibitor. This macrocyc…
RT @StephenVLiu: Online @MCT_AACR - preclinical account of TPX-0131, a potent, CNS-penetrant, next-generation #ALK inhibitor. This macrocyc…
Online @MCT_AACR - preclinical account of TPX-0131, a potent, CNS-penetrant, next-generation #ALK inhibitor. This macrocyclic molecule inhibits ALK, retains activity with G1202R, L1196M, and compound mutations. Eager to see clinical data! @OncoAlert #LCSM